November 16, 2018 09:39 AM ESTUpdated November 21, 06:30 AM
Peer Review

Japan­ese bil­lion­aire Mik­i­tani takes full con­trol of Rakuten As­pyr­i­an; HOX Ther­a­peu­tics taps Karl Kee­gan as CEO

Amber Tong

→ Hav­ing in­fused $150 mil­lion in­to Rakuten As­pyr­i­an weeks ago, Hi­roshi “Mick­ey” Mik­i­tani is step­ping up his con­trol on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times